EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PO41 | VENOUS THROMBOEMBOLISM IN PERIPHERAL BLOOD STEM CELL COLLECTION. A SINGLE CENTER EXPERIENCE

Società Italiana di Emostasi e Trombosi

Bleeding, Thrombosis and Vascular Biology · 16.04.2026 · 5 (s1)

DOI: 10.4081/btvb.2026.535 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bleeding, Thrombosis and Vascular Biology, online erschienen am 16.04.2026. Verfasst von Società Italiana di Emostasi e Trombosi. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Venous thromboembolism (VTE), particularly catheter-associated thrombosis (CAT), is a known complication of hematopoietic stem cell transplantation. Its link to peripheral blood stem cell (PBSC) collection is less well-defined. However, because central venous devices (CVD) are commonly used during mobilization, CAT remains an anticipated risk.

Aims

To define the incidence and describe clinical features, risk factors, and management of VTE in adults undergoing PBSC collection.

Methods

We retrospectively analyzed consecutive adults (>18 years) who underwent autologous PBSC collection at a single center between January 1, 2011, and December 31, 2025. We reviewed the clinical course from the start of mobilization through 30 days after collection, focusing on antithrombotics, VTE events, and their characteristics. Data collected included patient history, underlying disease, clinical features, and CVD-related factors.

Results

143 patients (60 female, 83 male; mean age 52.2 (19-72) years) underwent 147 hospitalizations for PBSC collection; 4 required repeated admission due to insufficient harvest. 138 (98.6%) had hematologic malignancies (myeloma: 91, non-Hodgkin lymphoma: 25, Hodgkin lymphoma: 18, acute leukemia: 7); 2 (1.4%) had multiple sclerosis (MS). Priming regimens varied by disease, but cyclophosphamide with GCSF predominated (131 cases, 90.1%). During hospitalization, antithrombotics (preferably low molecular weight heparins (LMWH) adjusted for thrombocytopenia) were given in 100 cases (69.9%). 11 (7.5%) courses of PBSC collection in 11 patients (7.7%; 4 male, 7 female; 29-62 years; myeloma: 5, Hodgkin lymphoma: 3, non-Hodgkin lymphoma: 2, MS: 1) were complicated by a VTE event (pulmonary embolism: 1, lower extremity: 1, upper extremity: 9). Initial LMWH prophylaxis was given to 10 and CVD to 7 patients. 9 events were linked to intravenous devices not used for collection (central: 6; peripheral: 3); 1 to the procedure. All were treated with LMWH and selectively switched to oral antithrombotics; no relevant bleeding or death was seen. Obesity (BMI > 30.0) was markedly more common in patients with VTE than in those without VTE (54.5% vs. 16.2%; P < 0.05), while no significant differences were observed in the other factors (age, comorbidities, medication, duration).

Conclusions

CAT is a relatively frequent complication of PBSC collection. Besides CVD use, obesity appears to be a potential risk factor. LMWH offers a safe treatment option.

Zitieren

APA

Trombosi, S. I. D. E. E. (2026). PO41 | VENOUS THROMBOEMBOLISM IN PERIPHERAL BLOOD STEM CELL COLLECTION. A SINGLE CENTER EXPERIENCE. Bleeding, Thrombosis and Vascular Biology, 5(s1). https://doi.org/10.4081/btvb.2026.535

Vancouver

Trombosi SIDEE. PO41 | VENOUS THROMBOEMBOLISM IN PERIPHERAL BLOOD STEM CELL COLLECTION. A SINGLE CENTER EXPERIENCE. Bleeding, Thrombosis and Vascular Biology. 2026;5(s1). doi:10.4081/btvb.2026.535

BibTeX
@article{Trombosi2026,
  author = {Trombosi, Società Italiana di Emostasi e},
  title = {PO41 | VENOUS THROMBOEMBOLISM IN PERIPHERAL BLOOD STEM CELL COLLECTION. A SINGLE CENTER EXPERIENCE},
  journal = {Bleeding, Thrombosis and Vascular Biology},
  year = {2026},
  volume = {5},
  number = {s1},
  doi = {10.4081/btvb.2026.535}
}
Kostenlos starten →